Sandip Zalawadiya, MD
Cardiovascular Disease · Nashville, TNNPI 1710115159
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,006 of the $17,331 with a category attached, or 80.8%. 4 manufacturers reported payments, led by Endotronix, Inc. at 59.2% of the total.
Across 41 payments — averaging $422.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endotronix, Inc.$10K
- Abbott$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30
- Medtronic$16
Across 133 payments — averaging $4733.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$223K
- Medtronic$202K
- Abbott$188K
- Actelion Pharmaceuticals, Ltd$16K
What the payments were for
- Consulting fees$14,00681%
- Travel & lodging$1,2757%
- Food & beverage$2,05012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endotronix, Inc. | 4 | $10,267 |
| Abbott | 35 | $7,018 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $30 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,331 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 123 | $169,632 |
| FarxigaDapagliflozin Propanediol | 57 | $75,041 |
| EliquisApixaban | 45 | $58,077 |
| JardianceEmpagliflozin | 32 | $47,025 |
| OzempicSemaglutide | 16 | $13,531 |
| Praluent PenAlirocumab | 12 | $11,075 |
| CorlanorIvabradine Hcl | 14 | $8,927 |
| XareltoRivaroxaban | 11 | $8,224 |
| Torsemide | 29 | $1,105 |
| Metoprolol Succinate | 37 | $938 |
| Eplerenone | 12 | $852 |
| Potassium Chloride | 25 | $789 |
| Bisoprolol Fumarate | 19 | $746 |
| Spironolactone | 102 | $610 |
| Carvedilol | 55 | $464 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.